A patient receives the first treatment based on Crispr-Cas9

In Philadelphia, a clinical trial has just begun that could revolutionize HIV treatment. A volunteer, who remained anonymous, was the first patient treated with EBT-101, a drug based on Crispr-Cas technology. ” EBT-101 can potentially address unmet needs people living with HIV/AIDS removing the viral DNA in your cell, thus eradicating the infection “, explains the Dr Kamel Khalili of Lewis Katz School of Medicine to temple university.

Thanks to a protease coupled to a guide RNA, the Crispr-Cas9 system is capable of cutting selected DNA fragments in cells.  © DataBase Center for Life Sciences

Thanks to a protease coupled to a guide RNA, the Crispr-Cas9 system is capable of cutting selected DNA fragments in cells. © DataBase Center for Life Sciences

AIDS: how to defeat HIV?

Eliminate HIV from infected cells

The EBT-101 was designed in collaboration with Excision Biotherapeuticscompany specialized in the design of therapies based on Crispr-Cas. Here, volunteers received AAV viral vectors intravenously (adeno-associated virus) type 9 that contains the genetic construct that will excise large portions of HIV DNA cells.

The goal of this phase 1/2 clinical trial is to test the safety and efficacy of various doses of EBT-101 in a handful of volunteers before rolling it out to larger cohorts. ” Official start of phase 1/2 clinical trials brings us closer to creating a potential treatment for HIV/AIDS said Amy Goldberg, physician and interim dean of the Lewis Katz School of Medicine.

The first results are not expected for many months, two medical centers in Missouri and New Jersey are currently recruiting volunteers to control the infection with antiretroviral treatment, and a third is about to open. If EBT-101 proves effective in this clinical trial, it would be an important step in research to cure HIV, an infection for which there is as yet no cure.

> Read more about Future

Read also in Future

Leave a Comment

Your email address will not be published. Required fields are marked *